Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Patients Who Achieve Durable Virologic Suppression: Longer Follow‐Up of an Observational Cohort Study
Open Access
- 1 December 2003
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 188 (11) , 1659-1665
- https://doi.org/10.1086/379741
Abstract
On the basis of studies with relatively short follow-up, treatment guidelines currently recommend that highly active antiretroviral therapy (HAART) be initiated in asymptomatic human immunodeficiency virus–infected patients when the CD4+ lymphocyte count is ⩽200 cells/mm3. We assessed the development of a new opportunistic infection or death among 1173 patients initiating HAART. Durable virologic suppression was defined as having more undetectable (+ lymphocyte counts of 350 cells/mm3 (P=.01). Among those with durable virologic suppression, there was no difference in disease progression between those with baseline CD4+ lymphocyte counts of 201–350 cells/mm3 and those with durable virologic suppression with baseline CD4+ lymphocyte counts of >350 cells/mm3 (P=.40). Initiating HAART with a CD4+ lymphoctye count of 200 cells/mm3Keywords
This publication has 0 references indexed in Scilit: